Abstract
[186gRe]Re-HEDP is a radiopharmaceutical used for pain palliation in bone metastases from various primary tumors. The negatron emitter with 〈Eβ〉 = 357 keV 186gRe is suitable to irradiate cancer and inflammatory cells, but it needs labeling bis-phosphonates as vectors to reach target tissue. Paper radiochromatography was used to evaluate the radiochemical purity of [186gRe]Re-HEDP in radiopharmaceutical solution as well as in biological samples (serum and urine) from treated patients, in order to follow bone-targeting and excretion. Following the activity concentration in each sample vs. time it is effective to elaborate a bio-kinetic model of the radiopharmaceutical and to optimize administration protocols.
Original language | English |
---|---|
Pages (from-to) | 117-123 |
Number of pages | 7 |
Journal | Journal of Radioanalytical and Nuclear Chemistry |
Volume | 277 |
Issue number | 1 |
DOIs | |
State | Published - 1 Jul 2008 |
ASJC Scopus subject areas
- Analytical Chemistry
- Nuclear Energy and Engineering
- Radiology Nuclear Medicine and imaging
- Pollution
- Spectroscopy
- Public Health, Environmental and Occupational Health
- Health, Toxicology and Mutagenesis